Navigation Links
Endo Pharmaceuticals Announces Proposal to Change Name of Parent Company and Rebrands Enterprise: Revealing an Innovative Corporate Structure Dedicated to Redefining Healthcare Value
Date:3/1/2012

es to restore bodily functions and to enable people to regain control of their lives, will operate as the company's medical devices arm.
  • Endo Pharmaceuticals, which has long been associated with high-quality branded products and certain specialty generics, will function as the branded pharmaceuticals-focused operating unit of the enterprise.
  • HealthTronics, a leading provider of genitourinary pathology (diagnostics) and other services such as cryotherapy and lithotripsy, will operate as the primary medical services partner for urologists and their practices. In addition, the recent acquisitions of MeridianEHR and UroChart, providers of EHR technology and physician practice management software, will be incorporated under the HealthTronics business line.
  • Qualitest, the sixth largest provider of generic medication in the U.S., will continue to manufacture high-quality generic pharmaceuticals that provide new options (tablets, caplets and liquids) for patients, providers and payers in the pain and women's health areas.
  • The next step will be to ask shareholders for their approval of the proposed new name at the annual meeting in May 2012. Shareholders will be notified through the company's proxy statement of the proposed change.

    About Endo

    Endo Pharmaceuticals Holdings Inc. (Endo) is a US-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through our operating companies: AMS, Endo Pharmaceuticals, HealthTronics and Qualitest, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike. Learn more at www.endo.com.

    Safe Harbor Statement

    This press release contai
    '/>"/>

    SOURCE Endo Pharmaceuticals Holdings Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
    (Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
    (Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
    Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
    ... Inc. (NYSE: HSP ), a global specialty pharmaceutical ... present at two upcoming conferences: , Raymond ... 8, 2011 (Tuesday) – Orlando, Fla.  9:15 a.m. Eastern time ... March 16, 2011 (Wednesday) – Miami, ...
    ... 2011 Dynatronics Corporation (Nasdaq: DYNT ) today ... 2010. Sales for the quarter ended December 31, ... December 31, 2009. Sales for the six months ended December ... period of the prior year. Net income ...
    Cached Medicine Technology:Dynatronics Announces Fiscal Second Quarter Results 2Dynatronics Announces Fiscal Second Quarter Results 3Dynatronics Announces Fiscal Second Quarter Results 4
    (Date:4/17/2014)... new study has found that India,s shocking rates of ... farmers who are clinging to tiny smallholdings less ... crops, such as cotton and coffee, that are highly ... a range of previous case studies that point to ... following the ,liberalisation, of the nation,s economy during the ...
    (Date:4/17/2014)... Giving patients adrenaline after they suffer a cardiac arrest ... of surviving long-term, according to new research conducted at ... who have a cardiac arrest get adrenaline, which has ... decades," said Dr. Steve Lin, an emergency physician and ... in medical treatment, long-term survival rates of patients who ...
    (Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
    (Date:4/16/2014)... of the embryo. It begins as a glob of identical ... become the cells of our lungs, muscles, nerves and all ... a feat of reverse tissue engineering, Stanford University researchers have ... cells to proliferate and transform into all of the specialized ...
    (Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
    Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
    ... involved in cancer, aging , , MONDAY, Sept. 1 (HealthDay ... active region of telomerase, an enzyme involved in both ... repeats of a short DNA sequence to the ends ... damage and loss of genetic information during cell division. ...
    ... appear to be at higher risk for psychiatric ... children, according to a report in the September ... one of the JAMA/Archives journals. In addition, low-birth-weight ... to have attention problems than suburban low-birth-weight children. ...
    ... the East coast distribute formula sample packs to new ... concerned about the potential for distributing these packs to ... September issue of Archives of Pediatrics & Adolescent ... practice is changing significantly. , "Packaged as smart diaper ...
    ... found it predicted outcome months after patient went home ... who sleep during the day while in rehabilitation have ... study, which was expected to be published in the ... the sleeping patterns and other predictors of recovery (e.g., ...
    ... drug from a biodegradable polymer , , MONDAY, Sept. 1 ... artery-opening, drug-eluting stents appears equally effective as older models ... study shows. , Stents are tiny mesh tubes inserted ... medicines that help prevent reclosure. The latest form of ...
    ... of a former U.S. soldier whose traumatic brain injuries (TBIs) were ... years after his discharge. The soldier, who suffered several concussions during ... and hearing/visibility issues on a daily basis. , ... ...
    Cached Medicine News:Health News:Secrets of Telomerase Revealed 2Health News:Study examines relationship between low birth weight and psychiatric problems in children 2Health News:Hospitals provide formula sample packs while medical organizations encourage breastfeeding 2Health News:Daytime Sleeping Linked to Poor Recovery in Older Patients 2Health News:New Type of Stent Appears Safe, Effective 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 3Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 4
    Topics include: ECG reading, ACLS (all the latest protocols and pearls), CHF, acute MI, cardiac testing, palpitations, pericarditis, arrhythmias, murmurs, athletes, valvular disease, endocarditis, sy...
    Cardiology Core Curriculum fills the gap between the preclinical pathophysiology texts and specialist volumes aimed at cardiologists. It covers clinical cardiology for medical students, cardiology tr...
    ... Surgery, published by Unbound ... digital resource that combines ... leading edge technology. It ... is specifically engineered to ...
    This electronic survival guide provides all the essential information that every surgery intern needs from Day 1 on the wards....
    Medicine Products: